Idiopathic pulmonary fibrosis (IPF) is an orphan disease affecting approximately 50,000 people in the United States. It is characterized by an irreversible loss of lung function, leading to high morbidity and mortality; most patients die within three to five years following diagnosis. Pirfenidone (Roche’s Esbriet) and nintedanib (Boehringer Ingelheim’s Ofev) are the only two drugs approved to treat adults with IPF. In addition to these two disease-modifying therapies (DMTs), physicians prescribe off-label medications (e.g., corticosteroids, anticoagulants) to IPF patients when the risk/benefit profile does not warrant treatment with pirfenidone or nintedanib or when patients cannot access these DMTs. Our Treatment Algorithms study provides national patient-level claims data to explore the use of key therapies in both newly diagnosed and recently treated IPF patients, providing insight into the current treatment landscape for this indication.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.
Markets covered: United States
Key companies: Novartis, Genentech, Viatris
Key drugs: Pirfenidone, imatinib, Revatio, nintedanib